Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITF2357 in active moderate to severe Crohn's disease
2004-004854-19Phase 2Completed
- Sponsor
- Italfarmaco
- Start
- Feb 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing ITF2357 with Placebo (2 arms). Primary endpoint: Percent change in CRP at week 8. Started Feb 2005; status: completed.
02
Drugs
givinostat
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2004-004854-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004854-19.